Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Puma Biotechnology (PBYI)

Puma Biotechnology (PBYI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 295,291
  • Shares Outstanding, K 50,391
  • Annual Sales, $ 230,470 K
  • Annual Income, $ 30,280 K
  • EBIT $ 34 M
  • EBITDA $ 45 M
  • 60-Month Beta 1.18
  • Price/Sales 1.25
  • Price/Cash Flow 6.73
  • Price/Book 2.50

Options Overview Details

View History
  • Implied Volatility 89.08% (-72.60%)
  • Historical Volatility 101.27%
  • IV Percentile 11%
  • IV Rank 4.23%
  • IV High 587.89% on 12/03/25
  • IV Low 67.07% on 08/29/25
  • Expected Move (DTE 6) 0.77 (13.05%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 102
  • Volume Avg (30-Day) 121
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 5,198
  • Open Int (30-Day) 4,878
  • Expected Range 5.10 to 6.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.19
  • Number of Estimates 2
  • High Estimate 0.19
  • Low Estimate 0.18
  • Prior Year 0.39
  • Growth Rate Est. (year over year) -51.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.76 +23.11%
on 11/14/25
5.87 -0.17%
on 12/12/25
+0.87 (+17.43%)
since 11/12/25
3-Month
4.30 +36.28%
on 09/17/25
6.12 -4.25%
on 11/10/25
+1.39 (+31.10%)
since 09/12/25
52-Week
2.58 +127.57%
on 04/09/25
6.12 -4.25%
on 11/10/25
+2.94 (+100.68%)
since 12/12/24

Most Recent Stories

More News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted...

PBYI : 5.86 (+2.27%)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...

PBYI : 5.86 (+2.27%)
Puma Biotech: Q3 Earnings Snapshot

Puma Biotech: Q3 Earnings Snapshot

PBYI : 5.86 (+2.27%)
Puma Biotechnology Reports Third Quarter 2025 Financial Results

Raising 2025 NERLYNX® revenue and net income estimates

PBYI : 5.86 (+2.27%)
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, Nov. 6, 2025, following the release of its third quarter 2025...

PBYI : 5.86 (+2.27%)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted...

PBYI : 5.86 (+2.27%)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on September 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...

PBYI : 5.86 (+2.27%)
Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the...

PBYI : 5.86 (+2.27%)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...

PBYI : 5.86 (+2.27%)
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues

Puma Biotechnology PBYI reported second-quarter 2025 adjusted earnings of 15 cents per share, which beat the Zacks Consensus Estimate of 11 cents. In the year-ago quarter, the company had incurred an...

IMCR : 36.80 (+2.79%)
EXAS : 101.50 (+0.14%)
PBYI : 5.86 (+2.27%)
CRMD : 11.49 (-2.13%)

Business Summary

Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United Statesfor the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche's Herceptin-based adjuvant therapy. The drug was also...

See More

Key Turning Points

3rd Resistance Point 6.14
2nd Resistance Point 6.00
1st Resistance Point 5.93
Last Price 5.86
1st Support Level 5.73
2nd Support Level 5.59
3rd Support Level 5.52

See More

52-Week High 6.12
Last Price 5.86
Fibonacci 61.8% 4.77
Fibonacci 50% 4.35
Fibonacci 38.2% 3.93
52-Week Low 2.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar